Home
Stelis Biopharma

Stelis Biopharma Market Share Analysis for May 2026

Contact OneSource for formulation expertise, specialized drug development and operational excellence with consistent regulatory compliance.

Industry: N/A

Domainstelis.com

Year Founded2013

Employees501 - 1000

Annual Revenue--

Stelis Biopharma

Stelis Biopharma (including company regionals)

stelis.com

See more website traffic and engagement information

Stelis Biopharma Revenue up to May 2026 is --

revenue generated by Stelis Biopharma top domains

Stelis Biopharma top domains revenue over 3 years

Revenue for Stelis Biopharma top domains

stelis.com--

See more with Sales Intelligence

Total visits to Stelis Biopharma's top domains

Understand Stelis Biopharma market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

stelis.com798

See more with Sales Intelligence

Avg. visit duration in Stelis Biopharma's top domains

Analyze Stelis Biopharma engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Stelis Biopharma's top domains

See how Stelis Biopharma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

stelis.com1.04

See more with Sales Intelligence

Stelis Biopharma top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Stelis Biopharma

These are the website technologies, by industry, used by Stelis Biopharma top domains

Widget (8)

Twemoji

Advertising (3)

DoubleClick

Conversion & Analytics (3)

Google Analytics

Email Services (3)

Microsoft Exchange Online

More Technologies

8

See all

News & Signals from Stelis Biopharma

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSteriscience, Inc. merges with Stelis Biopharma Ltd.In one of the largest and most integrated CDMO mergers in India, the 3 pillars - Strides, SteriScience, and Stelis Biopharma - combined into a Rs. 22,700 crore mammoth that is OneSource Specialty, and there are stark reasons why it is well positioned to capitalise on the GLP-1 revolution:

NewsStelis Biopharma Ltd partners with Synoptics Ltd.Strides Pharma | Stelis Biopharma announces closure of its transaction with Syngene.

NewsStelis Biopharma Ltd partnered with Syngene on Dec 3rd '23.Strides Pharma informed the bourses that Stelis Biopharma Ltd, the company’s biologics unit and a biopharmaceutical contract development and manufacturing organisation (CDMO), has entered into a binding term sheet with Syngene to divest its Unit 3 multi-modal facility at Bommasandra Industrial Area, Bengaluru.